IMM News: Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha - 9th Dec 2022, 12:00am

annb0t

Top 20
Immutep Limited

Media Release

First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein
Completed by WuXi Biologics

SYDNEY, AUSTRALIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the successful scale-up of the manufacturing of its lead product candidate eftilagimod alpha (...

>>> Read more: Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
 
Top Bottom